ArticleScientific reports2026
Continuous glucose monitoring reveals improved hyperglycemia and altered hypoglycemia target attainment after gastrectomy in patients with type 2 diabetes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate glycemic variability and biochemical profiles before and after gastrectomy using continuous glucose monitoring (CGM) and to evaluate whether postoperative improvements occur in blood glucose levels and biochemical parameters. We analyzed data from patients who underwent surgery for gastric cancer. Glucose profiles were assessed using a CGM device before gastrectomy and after discharge. All patients discontinued antidiabetic medications one day before surgery and resumed them only after reassessment at outpatient follow-up. CGM-derived metrics were evaluated according to international consensus recommendations, including time above range (TAR), time below range (TBR), time in range (TIR), CV (coefficient of variation), and MAGE (mean amplitude of glycemic excursions). A total of 33 patients were included. The mean duration of diabetes was 16.9 ± 10.4 years, and 12.1% were receiving insulin therapy. Mean glucose levels and TAR significantly decreased after gastrectomy while TIR significantly increased. Although TBR did not increase significantly, adherence to hypoglycemia targets worsened postoperatively. Glucose variability, assessed by CV, remained stable. Also, most patients maintained CV values below the threshold for glycemic instability. MAGE significantly decreased after surgery, indicating a reduction in large-amplitude glucose excursions. Among 16 patients whose postoperative medication changes were evaluated, seven (43.8%) reduced their antidiabetic medication after gastrectomy. In conclusion, despite the temporary discontinuation of antidiabetic medications, hyperglycemia improved without aggravation of glycemic variability, as reflected by increased TIR, stable CV and reduced MAGE. However, the achievement of hypoglycemia targets was reduced. Therefore, instead of routinely resuming preoperative antidiabetic regimens, postoperative glucose management should be individualized based on CGM-derived glycemic profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.